AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study

AIM ImmunoTech Inc AIM has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.
The company reported no serious adverse events, thus paving the way for dose escalation in Cohort 2.
An independent institute in the Netherlands is conducting the clinical study AMP-COV-100 (CHDR2049) to evaluate the safety and activity of repeated intranasal administration of Ampligen in Healthy Subjects.
AIM is the sponsor and is funding the clinical study.
The study protocol calls for the enrollment of eight healthy subjects in each of four Cohorts to receive Ampligen. Two additional healthy subjects in each Cohort will receive a placebo for a total of 40 healthy subjects.
AIM will continue to provide interim updates on the clinical trial.
Price Action: AIM shares were trading 0.65% higher at $2.34 during market trading hours on the last check Wednesday.